Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01314391|
Recruitment Status : Completed
First Posted : March 14, 2011
Last Update Posted : May 18, 2016
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in blood and tumor tissue samples from patients with Wilms tumor.
|Condition or disease||Intervention/treatment|
|Kidney Cancer Renal Failure||Genetic: mutation analysis Genetic: polymerase chain reaction Other: laboratory biomarker analysis|
- To determine whether Wilms Tumor (WT) patients without WT1-associated congenital anomalies or syndromes, but with end-stage renal disease (ESRD) unrelated to progressive bilateral tumors, carry germline WT1 mutations.
- To determine whether non-syndromic WT1 germline mutation carriers have a substantially higher incidence of ESRD than do WT patients who do not harbor WT1 mutations.
OUTLINE: Archived blood and tumor tissue specimens (or DNA isolated from these samples) are analyzed for WT1 mutations by gene sequencing and PCR.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Observational Model:||Case Control|
|Official Title:||Pilot Case-Control Study of WT1 Mutations in Wilms Tumor Patients Who Develop ESRD|
|Study Start Date :||August 2011|
|Actual Primary Completion Date :||May 2016|
- Higher incidence of ESRD in non-syndromic WT patients with germline WT1 mutations than WT patients without WT1 mutations
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01314391
|Principal Investigator:||Vicki Huff, PhD||M.D. Anderson Cancer Center|